Max Schmitt

Max Schmitt is Co-founder and CEO of Cannaflos GmbH, a biopharmaceutical company established in 2019, specializing in the endocannabinoid system and plant-based medicines to advance clinical-stage drug development for neuropathological conditions. As a lawyer, Max is focusing on all regulatory related topics related to market access and drug development. Cannaflos envisions a future where cannabinoid-based medicine (CBM) is fully recognized, validated, and integrated into modern healthcare.